The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment. Therefore, understanding the mechanisms underly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Cycle
Main Authors: Banelli, Barbara, Carra, Elisa, Barbieri, Federica, Würth, Roberto, Parodi, Federica, Pattarozzi, Alessandra, Carosio, Roberta, Forlani, Alessandra, Allemanni, Giorgio, Marubbi, Daniela, Florio, Tullio, Daga, Antonio, Romani, Massimo
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4825557/
https://ncbi.nlm.nih.gov/pubmed/26566863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2015.1090063
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados